Ketogenic diet registry for epilepsy: A cross-sectional feasibility study
- PMID: 39504880
- DOI: 10.1016/j.ejpn.2024.10.011
Ketogenic diet registry for epilepsy: A cross-sectional feasibility study
Abstract
We aimed to develop a registry ('Keto-Reg') for individuals with epilepsy referred for ketogenic dietary therapy (KDT) and to test feasibility of its implementation. The purpose of the registry is to provide a platform for collaborative research to answer specific research questions regarding long-term clinical and safety outcomes and to identify the most suitable candidates for KDT. Registry data items were determined via an international Delphi survey of KDT healthcare professionals, and then entered into an electronic platform. Three UK and two other European KDT centres entered data for 10 'patients' and reported on its acceptability and feasibility of use via questionnaire. 25 % of data was validated against medical records. A national survey was distributed and 19 parents and four young people were interviewed about a potential future patient/family section to the registry. Healthcare professionals from six continents responded to the Delphi (n = 153 round 1, n = 79 round 2); 70 items reached the agreement threshold. Registry data entry was accurate (0.3 % errors identified) and reported to be feasible and acceptable in the short-term. Lack of time was identified as the main barrier to longer-term implementation, with funded hours required. 87 % of the 53 survey responders and all interviewees viewed a patient/family section to be positive and feasible. We have shown healthcare professional involvement in Keto-Reg to be feasible in the short-term, and have identified what is necessary for the next stage: prospective longitudinal data entry from a larger number of international centres.
Keywords: Epilepsy; Ketogenic dietary therapy; Registry; Research database.
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest NES was previously supported for a research post by Vitaflo (International). She has received grants from Nutricia Advanced Medical Nutrition, Vitaflo (International), and Matthew's Friends charity, and honoraria from Nutricia Advanced Medical Nutrition, Vitaflo (International), and Dr Schaer. EGN has received consultancy payments and honoraria from Vitaflo (International), Kanso and Cerecin. EVL has received research grants from Nutricia Advanced Medical Nutrition and Vitaflo (international) and stichting de Merel, all money paid to the department. VW has received grants from Nutricia Advanced Medical Nutrition, Vitaflo (International), and Matthew's Friends charity, and honoraria from Nutricia Advanced Medical Nutrition, Vitaflo (International), and Cambrooke Ajinomoto. AMD is on the advisory boards of Nutricia, Takeda, Biocodex; speaker/industry trainer/symposia chair for GW Pharma, Nutricia Advanced Medical Nutrition, UCB, Zogenix. LL is a consultant/speaker for LivaNova, UCB Pharma, Zogenix, Eisai, Shire, Takeda, Novartis and Jazz Pharmaceuticals; and has a patent for Fenfluramine for the treatment of Dravet syndrome and infantile epilepsies assigned to his institution and licensed to Zogenix/UCB. ZS has received honoraria from Vitaflo (International), Nutricia Advanced Medical Nutrition and Danone Trading Medical B.V. JHC received grants from Vitaflo (International), GW Pharmaceuticals, Zogenix, Marinius, and Ovid; has received honoraria from Nutricia; and has a patent nutritional product (WO2013186570) and a patent anticonvulsant compound (WO2016038379A1) issued. CE received honoraria from GW Pharmaceuticals/JAZZ Pharmaceuticals. AS has received freelance payments from Vitaflo (International).
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
